Sedoanalgesia Strategies and their Potential Benefits in the Intensive Care Unit: Narrative Review of the Literature
DOI:
https://doi.org/10.17533/udea.iatreia.260Keywords:
Analgesia, Deep Sedation, Intensive Care Units, Respiration, Artificial, SepsisAbstract
Introduction: Sedoanalgesia is one of the main strategies used in the intensive care unit (ICU), aimed at reducing the presentation of associated adverse effects. However, to date there is a lack of an adequate description of its new and potential benefits.
Objectives: To critically review the available evidence on the selection of drugs used in sedoanalgesia and describe their potential pharmacological benefits in the critically ill patients.
Methods: A review of the literature was conducted from 1990 to 2022, considering the corresponding MeSH terms for sedation, benzodiazepines, dexmedetomidine, intravenous anesthetics, and intensive care unit. The information was extracted and synthesized in a structured manner according
to the recommendations of the SANRA guidelines.
Results: Lower rates of delirium and ICU stay were found for dexmedetomidine, while for midazolam and propofol a possible anti-inflammatory effect was found, and for ketamine a potential benefit in the hemodynamic profile was suggested.
Conclusions: Multiple beneficial effects of these drugs have been proposed, however, the evidence is scarce and studies with a better methodological design are needed to reach valid conclusions.
Downloads
References
(1) Ostermann ME, Keenan SP, Seiferling RA, Sibbald WJ. Sedation in the intensive care unit: a systematic review. JAMA [Internet]. 2000;283(11):1451-9. https://doi.org/10.1001/jama.283.11.1451
(2) Crippen DW. The role of sedation in the ICU patient with pain and agitation. Crit Care Clin [Internet]. 1990;6(2):369-92. https://doi.org/10.1016/S0749-0704(18)30380-4
(3) Mazzeo AJ. Sedation for the Mechanically Ventilated Patient. Crit. Care Clin [Internet]. 1995;11(4):937-955. https://doi.org/10.1016/S0749-0704(18)30047-2
(4) Richardson S, Shaffer JA, Falzon L, Krupka D, Davidson KW, Edmondson D. Meta-analysis of perceived stress and its association with incident coronary heart disease. Am J Cardiol [Internet]. 2012;110(12):1711-6. https://doi.org/10.1016/j.amjcard.2012.08.004
(5) Kress JP, Hall JB. Sedation in the mechanically ventilated patient. Crit Care Med [Internet]. 2006;34(10):2541-6. https://doi.org/10.1097/01.CCM.0000239117.39890.E3
(6) Mistraletti G, Donatelli F, Carli F. Metabolic and endocrine effects of sedative agents. Curr Opin Crit Care [Internet]. 2005;11(4):312-7. https://doi.org/10.1097/01.ccx.0000166397.50517.1f
(7) Preiser JC, Ichai C, Orban JC, Groeneveld AB. Metabolic response to the stress of critical illness. Br J Anaesth [Internet]. 2014;113(6):945-54. https://doi.org/10.1093/bja/aeu187
(8) Van-den-Berghe G. The neuroendocrine response to stress is a dynamic process. Best Pract Res Clin Endocrinol Metab [Internet]. 2001;15(4):405-19. https://doi.org/10.1053/beem.2001.0160
(9) Page V, McKenzie C. Sedation in the Intensive Care Unit. Curr Anesthesiol Rep [Internet]. 2021;11(2):92-100. Available from: https://pubmed.ncbi.nlm.nih.gov/33935593/
(10) Puntillo KA. Pain experiences of intensive care unit patients. Heart Lung [Internet]. 1990;19(5 Pt 1):526-33. Available from: https://pubmed.ncbi.nlm.nih.gov/2211161/
(11) Olsen BF, Valeberg BT, Jacobsen M, Småstuen MC, Puntillo K, Rustøen T. Pain in intensive care unit patients-A longitudinal study. Nurs Open [Internet]. 2020;8(1):224-231. https://doi.org/10.1002/nop2.621
(12) Sun X, Weissman C. The use of analgesics and sedatives in critically ill patients: physicians' orders versus medications administered. Heart Lung [Internet]. 1994;23(2):169-76. Available from: https://pubmed.ncbi.nlm.nih.gov/8206776/
(13) Cuesta JM, Singer M. The stress response and critical illness: a review. Crit Care Med [Internet]. 2012;40(12):3283-9. https://doi.org/10.1097/CCM.0b013e31826567eb
(14) Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA [Internet]. 1992;267(9):1244-52. https://doi.org/10.1001/jama.1992.03480090092034
(15) Pisani MA, Devlin JW, Skrobik Y. Pain and Delirium in Critical Illness: An Exploration of Key 2018 SCCM PADIS Guideline Evidence Gaps. Semin Respir Crit Care Med [Internet]. 2019;40(5):604-613. https://doi.org/10.1055/s-0039-1698809
(16) Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA [Internet]. 2004;291(14):1753-62. https://doi.org/10.1001/jama.291.14.1753
(17) Fan H, Sun M, Zhu JH. Early Sedation Depth and Clinical Outcomes in Mechanically Ventilated Patients with Sepsis. Iran J Public Health [Internet]. 2018;47(6):922-924. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077644/
(18) Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev [Internet]. 2019;4:5. https://doi.org/10.1186/s41073-019-0064-8
(19) Aitken LM, Bucknall T, Kent B, Mitchell M, Burmeister E, Keogh SJ. Protocol-directed sedation versus non-protocol-directed sedation in mechanically ventilated intensive care adults and children. Cochrane Database Syst Rev [Internet]. 2018;11(11):CD009771. https://doi.org/10.1002/14651858.CD009771.pub3
(20) Shehabi Y, Forbes AB, Arabi Y, Bass F, Bellomo R, Kadiman S et al. The SPICE III study protocol and analysis plan: a randomised trial of early goaldirected sedation compared with standard care in mechanically ventilated patients. Crit Care Resusc [Internet]. 2017;19(4):318-326. https://doi.org/10.1016/S1441-2772(23)00956-0
(21) Farina N, Alaniz C. Reconsidering Dexmedetomidine for Sedation in the Critically Ill: Implications of the SPICE III Trial. Ann Pharmacother [Internet]. 2020;54(5):504-508. https://doi.org/10.1177/1060028019890672
(22) Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA [Internet]. 2009;301(5):489-99. https://doi.org/10.1001/jama.2009.56
(23) Keating GM. Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting. Drugs [Internet]. 2015;75(10):1119-30. Available from: https://link.springer.com/article/10.1007/s40265-015-0419-5
(24) Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology [Internet]. 2003;98(2):428-36. https://doi.org/10.1097/00000542-200302000-00024
(25) Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth [Internet]. 2001;87(5):684-90. https://doi.org/10.1093/bja/87.5.684
(26) Srivastava U, Sarkar ME, Kumar A, Gupta A, Agarwal A, Singh TK et al. Comparison of clonidine and dexmedetomidine for short-term sedation of intensive care unit patients. Indian J Crit Care Med [Internet]. 2014;18(7):431-6. https://doi.org/10.4103/0972-5229.136071
(27) Pandharipande PP, Sanders RD, Girard TD, McGrane S, Thompson JL, Shintani AK, et al. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Crit Care [Internet]. 2010;14(2):R38. https://doi.org/10.1186/cc8916
(28) Kawazoe Y, Miyamoto K, Morimoto T, Yamamoto T, Fuke A, Hashimoto A, et al. Effect of Dexmedetomidine on Mortality and Ventilator-Free Days in Patients Requiring Mechanical Ventilation With Sepsis: A Randomized Clinical Trial. JAMA [Internet]. 2017;317(13):1321-1328. https://doi.org/10.1001/jama.2017.2088
(29) Zhang T, Mei Q, Dai S, Liu Y, Zhu H. Use of dexmedetomidine in patients with sepsis: a systematic review and meta-analysis of randomized-controlled trials. Ann Intensive Care [Internet]. 2022;12(1):81. https://doi.org/10.1186/s13613-022-01052-2
(30) Castillo RL, Ibacache M, Cortínez I, Carrasco-Pozo C, Farías JG, Carrasco RA, et al. Dexmedetomidine Improves Cardiovascular and Ventilatory Outcomes in Critically Ill Patients: Basic and Clinical Approaches. Front Pharmacol [Internet]. 2020;10:1641. https://doi.org/10.3389/fphar.2019.01641
(31) Sahinovic MM, Struys MMRF, Absalom AR. Clinical Pharmacokinetics and Pharmacodynamics of Propofol. Clin Pharmacokinet [Internet]. 2018;57(12):1539-1558. https://doi.org/10.1007/s40262-018-0672-3
(32) Barr J, Egan TD, Sandoval NF, Zomorodi K, Cohane C, Gambus PL et al. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology [Internet]. 2001;95(2):324-33. https://doi.org/10.1097/00000542-200108000-00011
(33) Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy [Internet]. 2005;25(5 Pt 2):8S-18S. https://doi.org/10.1592/phco.2005.25.5_Part_2.8S
(34) Nelson KM, Patel GP, Hammond DA. Effects From Continuous Infusions of Dexmedetomidine and Propofol on Hemodynamic Stability in Critically Ill Adult Patients With Septic Shock. J Intensive Care Med [Internet]. 2020;35(9):875-880. https://doi.org/10.1177/0885066618802269
(35) Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA [Internet]. 2012;307(11):1151-60. https://doi.org/10.1001/jama.2012.304
(36) Yoon SH. Concerns of the anesthesiologist: anesthetic induction in severe sepsis or septic shock patients. Korean J Anesthesiol [Internet]. 2012;63(1):3-10. https://doi.org/10.4097/kjae.2012.63.1.3
(37) Taniguchi T, Yamamoto K, Ohmoto N, Ohta K, Kobayashi T. Effects of propofol on hemodynamic and inflammatory responses to endotoxemia in rats. Crit Care Med [Internet]. 2000;28(4):1101-6. https://doi.org/10.1097/00003246-200004000-00032
(38) Booke M, Armstrong C, Hinder F, Conroy B, Traber LD, Traber DL. The effects of propofol on hemodynamics and renal blood flow in healthy and in septic sheep, and combined with fentanyl in septic sheep. Anesth Analg [Internet]. 1996;82(4):738-43. https://doi.org/10.1097/00000539-199604000-00011
(39) Marik PE. Propofol: an immunomodulating agent. Pharmacotherapy [Internet]. 2005;25(5 Pt 2):28S-33S. https://doi.org/10.1592/phco.2005.25.5_Part_2.28S
(40) Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev [Internet]. 2018;70(3):621-660. https://doi.org/10.1124/pr.117.015198
(41) Erstad BL, Patanwala AE. Ketamine for analgosedation in critically ill patients. J Crit Care [Internet]. 2016;35:145-9. https://doi.org/10.1016/j.jcrc.2016.05.016
(42) Patanwala AE, Martin JR, Erstad BL. Ketamine for Analgosedation in the Intensive Care Unit: A Systematic Review. J Intensive Care Med [Internet]. 2017;32(6):387-395. https://doi.org/10.1177/0885066615620592
(43) Himmelseher S, Kochs EF. Ready for a "breakthrough" with ketamine? A look at recent pharmacological insights! Curr Opin Anaesthesiol [Internet]. 2021;34(4):393-401. https://doi.org/10.1097/ACO.0000000000001017
(44) Mohrien KM, Jones GM, MacDermott JR, Murphy CV. Remifentanil, ketamine, and fospropofol: a review of alterative continuous infusion agents for sedation in the critically ill. Crit Care Nurs Q [Internet]. 2014;37(2):137-51. https://doi.org/10.1097/CNQ.0000000000000012
(45) Atchley E, Tesoro E, Meyer R, Bauer A, Pulver M, Benken S. Hemodynamic Effects of Ketamine Compared With Propofol or Dexmedetomidine as Continuous ICU Sedation. Ann Pharmacother [Internet]. 2022;56(7):764-772. https://doi.org/10.1177/10600280211051028
(46) Fluyau D, Revadigar N, Manobianco BE. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol [Internet]. 2018;8(5):147-168. https://doi.org/10.1177/2045125317753340
(47) Miller LG. Chronic benzodiazepine administration: from the patient to the gene. J Clin Pharmacol [Internet]. 1991;31(6):492-5. https://doi.org/10.1002/j.1552-4604.1991.tb03725.x
(48) Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med [Internet]. 1998;26(5):947-56. https://doi.org/10.1097/00003246-199805000-00034
(49) Kim SN, Son SC, Lee SM, Kim CS, Yoo DG, Lee SK, et al. Midazolam inhibits proinflammatory mediators in the lipopolysaccharide-activated macrophage. Anesthesiology [Internet]. 2006;105(1):105-10. https://doi.org/10.1097/00000542-200607000-00019
(50) Rossano F, Tufano R, Cipollaro de L'Ero G, Servillo G, Baroni A, Tufano MA. Anesthetic agents induce human mononuclear leucocytes to release cytokines. Immunopharmacol Immunotoxicol [Internet]. 1992;14(3):439-50. https://doi.org/10.3109/08923979209005403
(51) Taupin V, Jayais P, Descamps-Latscha B, Cazalaa JB, Barrier G, Bach JF, et al. Benzodiazepine anesthesia in humans modulates the interleukin-1 beta, tumor necrosis factor-alpha and interleukin-6 responses of blood monocytes. J Neuroimmunol [Internet]. 1991;35(1-3):13-9. https://doi.org/10.1016/0165-5728(91)90157-3
(52) Bidri M, Royer B, Averlant G, Bismuth G, Guillosson JJ, Arock M. Inhibition of mouse mast cell proliferation and proinflammatory mediator release by benzodiazepines. Immunopharmacology [Internet]. 1999;43(1):75-86. https://doi.org/10.1016/S0162-3109(99)00046-6
(53) Ulevitch RJ, Tobias PS. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol [Internet]. 1999;11(1):19-22. https://doi.org/10.1016/S0952-7915(99)80004-1
(54) Park BS, Lee JO. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med [Internet]. 2013;45(12):e66. https://doi.org/10.1038/emm.2013.97
(55) Sanghera JS, Weinstein SL, Aluwalia M, Girn J, Pelech SL. Activation of multiple proline-directed kinases by bacterial lipopolysaccharide in murine macrophages. J Immunol [Internet]. 1996 ;156(11):4457-65. https://doi.org/10.4049/jimmunol.156.11.4457
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Iatreia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
